NSNoah J. Silverstein

Noah J. Silverstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noah J. Silverstein has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection

    by Noah J Silverstein, Yetao Wang, Zachary Manickas-Hill, Claudia Carbone, Ann Dauphin, Brittany P Boribong, Maggie Loiselle, Jameson Davis, Maureen M Leonard, Leticia Kuri-Cervantes, et al.

    Background: Risk of severe COVID-19 increases with age, is greater in males, and is associated with lymphopenia, but not with higher burden of SARS-CoV-2. It is unknown whether effects of age and sex on abundance of specific lymphoid subsets explain these correlations.Methods: Multiple regression was used to determine the relationship between abundance of specific blood lymphoid cell types, age, sex, requirement for hospitalization, duration of hospitalization, and elevation of blood markers of systemic inflammation, in adults hospitalized for severe COVID-19 (n = 40), treated for COVID-19 as outpatients (n = 51), and in uninfected controls (n = 86), as well as in children with COVID-19 (n = 19), recovering from COVID-19 (n = 14), MIS-C (n = 11), recovering from MIS-C (n = 7), and pediatric controls (n = 17).Results: This observational study found that the abundance of innate lymphoid cells (ILCs) decreases more than 7-fold over the human lifespan – T cell subsets decrease less than 2-fold – and is lower in males than in females. After accounting for effects of age and sex, ILCs, but not T cells, were lower in adults hospitalized with COVID-19, independent of lymphopenia. Among SARS-CoV-2-infected adults, the abundance of ILCs, but not of T cells, correlated inversely with odds and duration of hospitalization, and with severity of inflammation. ILCs were also uniquely decreased in pediatric COVID-19 and the numbers of these cells did not recover during follow-up. In contrast, children with MIS-C had depletion of both ILCs and T cells, and both cell types increased during follow-up. In both pediatric COVID-19 and MIS-C, ILC abundance correlated inversely with inflammation. Blood ILC mRNA and phenotype tracked closely with ILCs from lung. Importantly, blood ILCs produced amphiregulin, a protein implicated in disease tolerance and tissue homeostasis. Among controls, the percentage of ILCs that produced amphiregulin was higher in females than in males, and people hospitalized with COVID-19 had a lower percentage of ILCs that produced amphiregulin than did controls.Conclusions: These results suggest that, by promoting disease tolerance, homeostatic ILCs decrease morbidity and mortality associated with SARS-CoV-2 infection, and that lower ILC abundance contributes to increased COVID-19 severity with age and in males.Funding: This work was supported in part by the Massachusetts Consortium for Pathogen Readiness and NIH grants R37AI147868, R01AI148784, F30HD100110, 5K08HL143183.


  • EJECTION FRACTION AND LIVER CHEMISTRY VARIABILITY IN MINORITY PATIENTS WITH HEART FAILURE

    by Maya Srinivasan, Perry Wengrofsky, Joseph Casillas, Noah Silverstein, Haytham Aboushi, Inna Bukharovich

  • Open Access

    Global profiling of human blood ILC subtypes reveals that NK cells produce homeostatic cytokine amphiregulin and sheds light on HIV-1 pathogenesis

    by Yetao Wang, Lawrence Lifshitz, Noah J. Silverstein, Esther Mintzer, Kevin Luk, Pam St. Louis, Michael A Brehm, Scot A. Wolfe, Steven G. Deeks, Jeremy Luban

    The interrelatedness of human blood innate lymphoid cell (ILC) subsets, and how they are perturbed by HIV-1, remains unclear. Transcriptional and chromatin profiling separated blood ILCs into ILC2s, ILCPs, one cluster that included CD56 dim and CD56 − NK cells, and CD56 hi NK cells that have features of both CD56 dim/– NK cells and ILCs. In contrast to mice, human NK cells expressed tissue repair protein amphiregulin (AREG), with greater production by CD56 hi NK cells than by ILCs. AREG was induced by TCF7/WNT signaling, IL-2, or IL-15, but not by inflammatory cytokines, and was inhibited by TGFB1, a cytokine elevated in people living with HIV-1. NK cell knockout of the TGFB1-stimulated WNT antagonist RUNX3 increased AREG production. In people living with HIV-1, AREG + NK cell percentage correlated with numbers of ILCs and CD4 + T cells, and correlated inversely with inflammatory cytokine IL-6. RNA-Seq showed increased antiviral gene expression in all ILC subsets from people who were HIV-1 viremic, and increased expression of anti-inflammatory gene MYDGF in CD56 hi NK cells from elite controllers. Functionally-defective CD56 − NK cells were increased in people living with HIV-1 in inverse correlation with CD56 dim NK cells, ILCs, and CD4 + T cells. Experiments with human PBMCs ex vivo and in humanized mice revealed that CD4 + T cells and their production of IL-2 prevented CD56 dim transition to CD56 − NK cells by activating mTOR, and, in people living with HIV-1, plasma IL-2 correlated with CD4 + T cell number but not with CD8 + T cells. These studies clarify how ILC subsets are interrelated and provide insight into how HIV-1 infection disrupts NK cells, including homeostatic functions of NK cells discovered here. Graphical


  • Open Access

    Innate lymphoid cells and disease tolerance in SARS-CoV-2 infection

    by Noah J. Silverstein, Yetao Wang, Zachary Manickas-Hill, Claudia C. Carbone, Ann Dauphin, Jonathan Z. Li, Bruce D. Walker, Xu G. Yu, Jeremy Luban, Brittany P. Boribong, et al.

    BACKGROUND Risk of severe coronavirus disease 2019 (COVID-19) increases with age, is greater in males, and is associated with decreased numbers of blood lymphoid cells. Though the reasons for these robust associations are unclear, effects of age and sex on innate and adaptive lymphoid subsets, including on homeostatic innate lymphoid cells (ILCs) implicated in disease tolerance, may underlie the effects of age and sex on COVID-19 morbidity and mortality. METHODS Flow cytometry was used to quantitate subsets of blood lymphoid cells from people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comparing those hospitalized with severe COVID-19 (n=40) and those treated as outpatients for less severe disease (n=51). 86 healthy individuals served as controls. The relationship between abundance of specific blood lymphoid cell types, age, sex, hospitalization, duration of hospitalization, and elevation of blood markers for systemic inflammation, was determined using multiple regression. RESULTS After accounting for effects of age and sex, hospitalization for COVID-19 was associated with 1.78-fold fewer ILCs (95%CI: 2.34–1.36; p = 4.55 x 10−5) and 2.31-fold fewer CD16+ natural killer (NK) cells (95%CI: 3.1–1.71; p = 1.04 x 10−7), when compared to uninfected controls. Among people infected with SARS-CoV-2, the odds ratio for hospitalization, adjusted for age, sex, and duration of symptoms, was 0.413 (95%CI: 0.197–0.724; p = 0.00691) for every 2-fold increase in ILCs. In addition, higher ILC abundance was associated with less time spent in the hospital and lower levels of blood markers associated with COVID-19 severity: each two-fold increase in ILC abundance was associated with a 9.38 day decrease in duration of hospital stay (95% CI: 15.76–3.01; p= 0.0054), and decrease in blood C-reactive protein (CRP) by 46.29 mg/L (95% CI: 71.34–21.24; p = 6.25 x 10−4), erythrocyte sedimentation rate (ESR) by 11.04 mm/h (95% CI: 21.94–0.13; p = 0.047), and the fibrin degradation product D-dimer by 1098.52 ng/mL (95% CI: 1932.84–264.19; p = 0.011). CONCLUSIONS Both ILCs and NK cells were depleted in the blood of people hospitalized for severe COVID-19, but, among lymphoid cell subsets, only ILC abundance was independently associated with the need for hospitalization, duration of hospital stay, and severity of inflammation. These results indicate that, by promoting disease tolerance, homeostatic ILCs protect against morbidity and mortality in SARS-CoV-2 infection, and suggest that reduction in the number of ILCs with age and in males accounts for the increased risk of severe COVID-19 in these demographic groups.


  • Open Access

    Cytotoxic CD4 Development Requires CD4 Effectors to Concurrently Recognize Local Antigen and Encounter Infection-Induced IL-15

    by Priyadharshini Devarajan, Allen M. Vong, Catherine H. Castonguay, Noah J. Silverstein, Olivia Kugler-Umana, Bianca L. Bautista, Karen A. Kelly, Jeremy Luban, Susan L. Swain, Michael C Jones

    Cytotoxic CD4 T cells (ThCTL) are tissue-resident effectors that enhance viral clearance by MHC-II-restricted cytotoxicity of infected cells. Using a model of influenza A virus (IAV) infection, we identify key factors that drive CD4 effectors to differentiate into lung-resident ThCTL. We find that, to become ThCTL, CD4 effectors must again recognize cognate antigen on antigen presenting cells (APC) within the lung. Different APC subsets can drive this transition, including dendritic cells, B cells, and to a lesser extent non-hematopoietic MHC-II + APC. CD28 co-stimulation is not required and can reduce ThCTL development. In contrast, T follicular helper cells (T FH ) that are another specialized CD4 effector subset, require CD28 during this time. Optimal ThCTL generation also requires ongoing infection in the effector phase, that acts independently of antigen presentation. The mechanism involves production of Type I IFN, that induces IL-15 which acts to support further differentiation of CD4 effectors to ThCTL. The multiple spatial, temporal and cellular requirements for ThCTL generation from CD4 effectors described here would be expected to prevent cytotoxic CD4 responses in the lung after pathogen has already been cleared, while ensuring the development of potent lung-restricted ThCTL effectors when pathogen persists.


  • The piRNA Response to Retroviral Invasion of the Koala Genome

    by Tianxiong Yu, Birgit S. Koppetsch, Sara Pagliarani, Stephen Johnston, Noah J. Silverstein, Jeremy Luban, Keith Chappell, Zhiping Weng, William E. Theurkauf


  • Open Access

    A Cross-Sectional Study of Dietary and Genetic Predictors of Blood Folate Levels in Healthy Young Adults

    by Daniel Cummings, Kevin F. Dowling, Noah J. Silverstein, Alexandra S. Tanner, Hamdi Eryilmaz, Jordan W. Smoller, Joshua L. Roffman

    Since 1998, the U.S. has mandated folic acid (FA) fortification of certain grain products to reduce the risk of neural tube defects. Folate intake and red blood cell (RBC) folate concentrations increased substantially post-intervention, although recent studies raise concerns about the level of ongoing benefit. This study investigated blood folate level determinants in healthy young adults, including intake of naturally occurring food folate, synthetic FA, and the interaction of naturally occurring food folate with a common missense variant in the FOLH1 gene thought to affect absorption. Participants (n = 265) completed the Diet History Questionnaire II, RBC folate testing, and were genotyped for the 484T>C FOLH1 variant. Men reported significantly greater intake of all folate sources except for supplemental FA, but RBC folate levels did not significantly differ by sex. Synthetic FA was a stronger predictor of RBC folate than naturally occurring food folate. In the largest racial group, synthetic FA and the interaction of FOLH1 genotype with naturally occurring food folate significantly predicted RBC folate, with the overall model accounting for 13.8% of the variance in RBC folate levels. Blood folate levels rely on a complex interaction of natural and synthetic folate intake as well as FOLH1 genotype.


  • Open Access

    Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial

    by J L Roffman, L J Petruzzi, A S Tanner, H E Brown, H Eryilmaz, N F Ho, M Giegold, N J Silverstein, T Bottiglieri, D S Manoach, et al.

    Folic acid supplementation confers modest benefit in schizophrenia, but its effectiveness is influenced by common genetic variants in the folate pathway that hinder conversion to its active form. We examined physiological and clinical effects of l-methylfolate, the fully reduced and bioactive form of folate, in schizophrenia. In this randomized, double-blind trial, outpatients with schizophrenia (n=55) received l-methylfolate 15 mg or placebo for 12 weeks. Patients were maintained on stable doses of antipsychotic medications. The pre-defined primary outcome was change in plasma methylfolate at 12 weeks. Secondary outcomes included change in symptoms (Positive and Negative Syndrome Scale (PANSS), Scale for Assessment of Negative Symptoms, Calgary Depression Scale for Schizophrenia), cognition (Measurement and Treatment Research to Improve Cognition in Schizophrenia composite) and three complementary magnetic resonance imaging measures (working memory-related activation, resting connectivity, cortical thickness). Primary, mixed model, intent-to-treat analyses covaried for six genetic variants in the folate pathway previously associated with symptom severity and/or response to folate supplementation. Analyses were repeated without covariates to evaluate dependence on genotype. Compared with placebo, l-methylfolate increased plasma methylfolate levels (d=1.00, P=0.0009) and improved PANSS Total (d=0.61, P=0.03) as well as PANSS Negative and General Psychopathology subscales. Although PANSS Total and General Psychopathology changes were influenced by genotype, significant PANSS Negative changes occurred regardless of genotype. No treatment differences were seen in other symptom rating scales or cognitive composite scores. Patients receiving l-methylfolate exhibited convergent changes in ventromedial prefrontal physiology, including increased task-induced deactivation, altered limbic connectivity and increased cortical thickness. In conclusion, l-methylfolate supplementation was associated with salutary physiological changes and selective symptomatic improvement in this study of schizophrenia patients, warranting larger clinical trials. ClinicalTrials.gov, NCT01091506.


  • Open Access

    Interleukin-17: Why the Worms Squirm

    by Noah J. Silverstein, Jun R. Huh